Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Manidipine hydrochloride and irbesartan compound tablet for treating high blood pressure and preparation method

A technology of manidipine hydrochloride and compound tablets, which is applied in the field of medicine, can solve the problems of antihypertensive effect, target organ protection, difference in tolerance, and different clinical status, achieve good dissolution rate and stability, reduce drug dosage, good synergistic effect

Inactive Publication Date: 2017-04-26
XUCHANG HENGSHENG PHARMA
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above drugs can be combined in a variety of ways, but the antihypertensive effect, target organ protection effect and tolerance of different combination regimens may be significantly different, so the clinical status is different

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Manidipine hydrochloride and irbesartan compound tablet for treating high blood pressure and preparation method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] A compound tablet of manidipine hydrochloride and irbesartan for the treatment of hypertension, the total weight of the compound tablet is 264mg, wherein manidipine hydrochloride 5mg, irbesartan 75mg, colloidal silicon dioxide 30mg, starch 63mg, povidone 12mg, lactose-hydrate 74mg and magnesium stearate 5mg.

[0024] The preparation method of above-mentioned compound tablet, comprises the following steps:

[0025] (1) Take various raw materials according to the above weight percentages, first pass manidipine hydrochloride and irbesartan through a 100-mesh sieve, and carry out ultrafine grinding respectively to control the particle size of manidipine hydrochloride and irbesartan All D90≤25μm, spare;

[0026] (2) Disperse manidipine hydrochloride, irbesartan, starch and part of colloidal silicon dioxide in water to prepare a suspension for later use;

[0027] (3) Add povidone, lactose-hydrate and remaining colloidal silicon dioxide to the suspension in step (2), mix wel...

Embodiment 2

[0031] A compound tablet of manidipine hydrochloride and irbesartan for the treatment of hypertension, the total weight of the compound tablet is 259.1mg, wherein manidipine hydrochloride 4.9mg, irbesartan 72.6mg, colloidal silicon dioxide 31.5mg, starch 61.8mg, povidone 10.9mg, lactose hydrate 72.6mg and magnesium stearate 4.8mg.

[0032] The preparation method of above-mentioned compound tablet, comprises the following steps:

[0033] (1) Take various raw materials according to the above weight percentages, first pass manidipine hydrochloride and irbesartan through a 100-mesh sieve, and carry out ultrafine grinding respectively to control the particle size of manidipine hydrochloride and irbesartan All D90≤25μm, spare;

[0034] (2) Disperse manidipine hydrochloride, irbesartan, starch and part of colloidal silicon dioxide in water to prepare a suspension for later use;

[0035] (3) Add povidone, lactose-hydrate and remaining colloidal silicon dioxide to the suspension in s...

Embodiment 3

[0039] A compound tablet of manidipine hydrochloride and irbesartan for the treatment of hypertension, the total weight of the compound tablet is 262.4mg, wherein manidipine hydrochloride 4.9mg, irbesartan 70.8mg, colloidal silicon dioxide 32.2mg, starch 61.8mg, povidone 10.9mg, lactose hydrate 76.6mg and magnesium stearate 5.2mg.

[0040] The preparation method of above-mentioned compound tablet, comprises the following steps:

[0041](1) Take various raw materials according to the above weight percentages, first pass manidipine hydrochloride and irbesartan through a 100-mesh sieve, and perform ultrafine grinding respectively to control the particle size of manidipine hydrochloride and irbesartan All D90≤25μm, spare;

[0042] (2) Disperse manidipine hydrochloride, irbesartan, starch and part of colloidal silicon dioxide in water to prepare a suspension for later use;

[0043] (3) Add povidone, lactose-hydrate and remaining colloidal silicon dioxide to the suspension in step...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention relates to a manidipine hydrochloride and irbesartan compound tablet for treating high blood pressure and a preparation method. According to the compound tablet, manidipine hydrochloride and irbesartan serve as the effective compositions of the drug, and the compound tablet is prepared from, by weight, 1.5-2.0% of manidipine hydrochloride, 25-30% of irbesartan, 10-14% of colloidal silicon dioxide, 20-24% of adjuvant material I, 4-5% of adjuvant material II, 28-32% of lactose- hydrate and 1-2% of magnesium stearate. The manidipine hydrochloride and irbesartan compound tablet is reasonable in formula, medicine dose is reduced, the effect of lowering blood pressure is enhanced, the compound composed of manidipine hydrochloride and irbesartan has good synergistic effects, the preparation process is simple and easy to implement, the production cost is low, and the preparation method is suitable for large-scale industrial production.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a compound tablet of manidipine hydrochloride and irbesartan for treating hypertension and a preparation method thereof. Background technique [0002] With the development of social economy and the change of residents' lifestyle, chronic non-communicable diseases (referred to as chronic diseases) have become a major public health problem affecting the health of residents in my country and even the world, and hypertension is one of the chronic diseases with a high prevalence rate. It is also the most important risk factor for cardiovascular and cerebrovascular diseases. According to the World Health Organization (WHO) statistics, in 2012, the number of deaths from cardiovascular diseases in the world was 17 million, accounting for 46% of the deaths from chronic diseases, of which 9.4 million died from complications of hypertension, which has become the primary risk factor affectin...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/496A61K31/4184A61K9/20A61K47/36A61K47/04A61K47/32A61K47/26A61K47/12A61P9/12
CPCA61K31/496A61K9/2009A61K9/2013A61K9/2018A61K9/2027A61K9/2059A61K31/4184A61K2300/00
Inventor 杨豪杰谷志勇蚩晓娜吕亚军
Owner XUCHANG HENGSHENG PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com